Figure 4. Evidence network plot of 17 treatment regimens which were included in this network meta-analysis.
(A: chemotherapy; B: bevacizumab + chemotherapy; C: cetuximab + chemotherapy; D: panitumumab + chemotherapy; E: sunitinib + chemotherapy; F: cediranib + chemotherapy; G: celecoxib + chemotherapy; H: sorafenib + chemotherapy; I: axitinib + chemotherapy; J: trebananib + chemotherapy; K: conatumumab + chemotherapy; L: ganitumab + chemotherapy; M: gefitinib + chemotherapy; N: panitumumab + bevacizumab + chemotherapy; O: brivanib + cetuximab + chemotherapy; P: axitinib + bevacizumab + chemotherapy; Q: cetuximab + bevacizumab + chemotherapy).